First Patient Treated in Microbion’s Phase IIA Orthopaedic Infection Trial

Microbion enrolled the first patient in its U.S. Phase IIA study of MBN-101 candidate for treatment of orthopaedic implant-related infections.

MBN-101 is the lead in a new class of drugs under development by Microbion to combat infections, including multi-drug-resistant strains. The study is partially funded by a grant from the U.S. Department of Defense (DOD), Military Infectious Diseases Research Program and managed by the University of Pennsylvania. DOD has provided grants to Microbion in the past.

Numerous anti-infection approaches are in varying stages of development, such as BONESUPPORT’s drug-eluting bone substitute, PolyPid’s bone void filler, Silver Bullet’s antimicrobial devices, Tyber Medical’s BioTy surface treatment; that’s not even including the use of disposable instruments. The topic is of critical importance to just about every stakeholder along the chain of product commercialization.

Sources: Microbion Corporation, ORTHOWORLD Inc.